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Performance of four ischemic stroke 
prognostic scores in a Brazilian population
Desempenho de quatro escalas de prognóstico de AVCI em uma população brasileira 
Gustavo W. Kuster1,2,3, Lívia A. Dutra1,2,4,  Israel P. Brasil1,2, Evelyn P. Pacheco1,2, Márcio J. C. Arruda1, Cristiane 
Volcov1, Renan B. Domingues1,2,5
The prediction of ischemic stroke outcome may help phy-
sicians in their acute treatment decisions. Some scores have 
been developed for predicting prognosis after ischemic stroke 
(IS). The National Institutes of Health Stroke Scale (NIHSS) 
strongly predicts stroke prognosis, is well validated, and is 
routinely used, both in clinical and research settings1. The 
Stroke Prognostication Using Age and NIHSS (SPAN-100) 
index, which combines age and NIH Stroke Scale, was shown 
to be a simple method for estimating the clinical response 
and risk of hemorrhagic complications after tissue-type 
plasminogen activator (tPA) for acute IS2. The Acute Stroke 
Registry and Analysis of Lausanne (ASTRAL) score (age, se-
verity, time delay between stroke onset and admission, range 
of visual deficit, acute glucose, and levels of consciousness) 
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ABSTRACT
Objective: Ischemic stroke (IS) prognostic scales may help clinicians in their clinical decisions. This study aimed to assess the performance 
of four IS prognostic scales in a Brazilian population. Method: We evaluated data of IS patients admitted at Hospital Paulistano, a Joint 
Commission International certified primary stroke center. In-hospital mortality and modified Rankin score at discharge were defined as 
the outcome measures. The performance of National Institutes of Health Stroke Scale (NIHSS), Stroke Prognostication Using Age and 
NIHSS (SPAN-100), Acute Stroke Registry and Analysis of Lausanne (ASTRAL), and Totaled Health Risks in Vascular Events (THRIVE) were 
compared. Results: Two hundred six patients with a mean ± SD age of 67.58 ± 15.5 years, being 55.3% male, were included. The four scales 
were significantly and independently associated functional outcome. Only THRIVE was associated with in-hospital mortality. With area 
under the curve THRIVE and NIHSS were the scales with better performance for functional outcome and THRIVE had the best performance 
for mortality. Conclusion: THRIVE showed the best performance among the four scales, being the only associated with in-hospital mortality. 
Keywords: ischemic stroke, prognostic scales, NIHSS, THRIVE, Brazil.
RESUMO
Objetivo: Escalas de avaliação prognóstica do acidente vascular cerebral isquêmico (AVCI) podem ajudar decisões clinicas. O objetivo 
deste estudo foi avaliar o desempenho de quatro escalas prognósticas em uma população brasileira. Método: Foram avaliados os dados 
de pacientes admitidos com AVCI no Hospital Paulistano, um hospital acreditado pela “Joint Commission International”. A mortalidade 
intra-hospitalar e a escala de Rankin foram definidos como desfechos de evolução clínica. O desempenho de quatro escalas: National 
Institutes of Health Stroke Scale (NIHSS), Stroke Prognostication Using Age and NIHSS (SPAN-100), Acute Stroke Registry and Analysis 
of Lausanne (ASTRAL) e Totaled Health Risks in Vascular Events (THRIVE) foi comparado. Resultados: Foram incluídos duzentos e seis 
pacientes, com uma idade média de 67,58 ± 15,5 anos, sendo 55,3% dos sexo masculino. Todas as quatro escalas associaram-se de forma 
independente com prognóstico funcional. Apenas o THRIVE correlacionou-se com a mortalidade hospitalar. O THRIVE e o NIHSS tiveram 
melhor desempenho para prognóstico funcional e o THRIVE teve o melhor desempenho para mortalidade pela área sob a curva. Conclusão: 
O THRIVE mostrou-se a escala com melhor performance, sendo a única correlacionada com a mortalidade hospitalar. 
Palavras-chave: acidente vascular cerebral isquêmico, escalas de prognóstico, NIHSS, THRIVE, Brasil.
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is a six items score, at hospital admission, that showed to be 
potentially useful for clinical practice3. Totaled Health Risks 
in Vascular Events (THRIVE) score (totaled health risks in 
vascular events) is calculated with age, NIHSS, and the pres-
ence of hypertension, diabetes mellitus, and atrial fibrillation 
and was validated to predicting clinical outcome and hemor-
rhagic transformation in patients receiving tPA and showed 
to be a simple score to help clinicians to estimate outcome 
and death after acute IS4. These four scores were not yet 
compared and their reproducibility has been tested only in 
Europe, North America, and Asia.
Stroke is the leading cause of death and disability in 
Brazil5. IS accounts for more than 80% of all stroke types in 
Brazil6. In recent years, a growing number of stroke centers 
have been settled in this country7. Consequently, an increas-
ing number of patients with acute IS have benefited from 
validated therapies, including the use of tPA8. However, only 
few studies have evaluated IS outcome in Brazil9 and none 
of them have assessed the utility of prognostic scores in a 
Brazilian population. The aim of the present study was to 
compare the performance of NIHSS, SP-100, ASTRAL, and 
THRIVE scores to predict in-hospital mortality and function-
al outcome in an acute IS Brazilian population.
METHOD
Charts of patients assisted at Hospital Paulistano, a Joint 
Commission International certified stroke center located in the 
central region of São Paulo, between 2012 and 2014, were reviewed. 
This study protocol was approved by the Ethics Committee on 
Research of Hospital Paulistano (Amil Stroke Network).
Patients and procedures
We retrospectively evaluated the clinical records of all pa-
tients admitted with suspected or confirmed stroke. The diagno-
ses were made by neurologists with expertise in cerebrovascular 
disease through clinical and radiological evaluation. All patients 
underwent at least one computed tomography scan of the brain 
(CT scan) to confirm the diagnosis. Only patients diagnosed as 
having IS were included in the analysis.
Age, gender, stroke risk factors (hypertension, smoking, 
familial history of vascular diseases, diabetes, previous stroke 
or transient ischemic attack) were compiled. Data on clinical 
presentation, NIHSS, capillary glucose level, and vital signs 
on admission were also recorded.
Prognostic scores
The prognostic scales as well as their cut-offs were 
used as described in previous studies. According to NIHSS 
patients were allocated into three subgroups (0 to 5, 6 to 15, 
and ≥ 16)1. SPAN-100 was calculated by the sum of the age 
in years and the NIHSS. The adopted cut off for SPAN-100 
was 100 and patients were divided into two groups, one with 
SPAN-100 < 100 and other with SPAN-100 ≥ 1002. ASTRAL 
score was calculated by the sum of age (1 point for every 
5 years), NIHSS, time delay from onset to admission (0 points 
when onset to admission was < 3 hours, 2 points when it was 
more than 3 hours), range of visual deficit (0 points in the ab-
sence of visual field defect, 2 points for any stroke-related vis-
ual field defect), acute glucose < 3.7 mmol/L or > 7.3 mmol/L 
(1 point), and decreased level of consciousness (3 points). An 
ASTRAL score ≥ 31 was adopted as an indicator of unfavoura-
ble outcome3. THRIVE score was calculated by the sum of age 
(1 point for age of 60 to 79 years, 2 points for an age ≥ 80 years), 
2 points for a NIHSS of 11 to 20, 4 points for a NIH ≥ 21, and 
1 point for each hypertension, diabetes mellitus, and fibrilla-
tion. The THRIVE ranged from 0 to 9 and the patients were 
divided in three subgroups (0 to 2, 3 to 5, and 6 to 9)4.
Data analysis
Statistical analysis was performed using SPSS version 
15.0 for Windows. The confidence interval was of 95% and 
the significance level was set at p < 0.05. Normality was as-
sessed using the Kolmogorov-Smirnov test. In-hospital mor-
tality and modified Rankin score (mRs) at discharge, whereby 
the patients were divided in two groups, one with mRS ≤ 2 
and other with mRs > 2, were defined as outcomes measures. 
Univariate analysis was carried out with Mann-Whitney test 
for continuous variables and chi-square for categorical vari-
ables. A binary logistic regression analysis was performed 
with mRS and in-hospital mortality as dependent variables. 
A sensitivity analysis was conducted to compare the three 
scores. Area under the receiver operator curves (AUROC) 
and 95% CIs were calculated as a measure of predictive 
ability. According to the AUROC result the predictive ability 
was considered excellent (0.9 to 0.99), good (0.8 to 0.89), fair 
(0.7 to 0.79), poor (0.6 to 0.69), and failure (0.5 to 0.59).
RESULTS
Three hundred fifty one patients were admitted with 
stroke or suspected stroke in the period of the study. Among 
them, two hundred six patients (58.7%) had the diagnosis of 
IS and were included in the analysis. The mean ± standard 
deviation (SD) age was 67.58 ± 15.5 years and 55.3% of pa-
tients were male. Table 1 shows the comparisons of the char-
acteristics of patients who had favorable functional outcome 
(mRs ≥ 2) with those of patients with poor functional outcome 
(mRs > 2). By univariate analysis, patients with mRs > 2 had 
higher age (p  =  0.002), higher percentage of NIHSS ≥ 16 at 
admission (p < 0.001), higher percentage of SPAN-100 ≥ 100 
(p < 0.001), higher percentage of ASTRAL ≥ 31 (p < 0.001), 
and higher percentages of THRIVE 3 to 5 and THRIVE  >  5 
(p < 0.001). After adjusted analysis, none of these variables 
were independently associated with mRs > 2. Table 2 shows 
the comparisons of baseline characteristics of survivors and 
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patients who died during hospitalization. No significant dif-
ferences were found between these two groups.
NIHSS subgroups were fairly predictive of mRs  >  2 
(AUROC 0.754; 0.644 to 0.810, p < 0.001) and were not pre-
dictive of in-hospital mortality (AUROC 0.546; 0.409 to 0.683, 
p = 0.495). SPAN-100 ≥ 100 was poorly predictive of poor func-
tional outcome (AUROC 0.591; 0.5 to 0.683, p  =  0.041) and 
was not predictive of in-hospital mortality (AUROC 0.520; 
0.386 to 0.654, p  =  0.766). ASTRAL ≥ 31 was poorly predic-
tive of mRs > 2 (AUROC 0.668; 0.577 to 0.758, p < 0.001) and 
not predictive of in-hospital mortality (AUROC 0.556; 0.428 
to 0.705, p  =  0.321). THRIVE subgroups were fairly predic-
tive of mRs > 2 (AUROC 0.720; 0.641 to 0.800, p < 0.001) and 
were poorly predictive of in-hospital mortality (AUROC 0.636; 
0.513 to 0.758, p = 0.042) (Figure).
DISCUSSION
In the present study none of the scores demonstrated good 
or excellent ability to predict in-hospital mortality and function-
al outcome in the studied population. THRIVE score was the 
only score to predict death but the accuracy was poor. THRIVE 
and NIHSS were fairly accurate to predict worse functional 
outcome at hospital discharge. In previous studies THRIVE 
was shown to be a good predictor of clinical outcome, hemor-
rhagic transformation, and outcome after endovascular10 and 
intravenous stroke treatment11,12. This score has been previous-
ly tested in North American, European, and Asian populations; 
however, to the best of our knowledge, this was the first study 
to evaluate this score in a South American population. The 
THRIVE score can be easily calculated and can be quickly per-
formed with data routinely obtained during the initial clinical 
evaluation, such as age, NIHSS, and risk factors (hypertension, 
diabetes, and atrial fibrillation), without the need of neuroim-
aging and laboratory testing4. Despite the fact THRIVE was the 
score with better performance, it had not an AUROC above the 
threshold of 0.8, which is required for clinical use. These results 
should be interpreted cautiously since our study was small 
and was carried out in a single institution. Future studies are 
needed to better assess and validate the use of THRIVE in the 
Brazilian population.
SPAN-100 did not predict well in-hospital mortal-
ity and functional outcome. This finding is in line with 
a previous study also demonstrating poor performance 
of SPAN-100 to predict outcomes at 3 and 12 months in 
Table 1. Clinical characteristics of patients according to the 
mRs at hospital discharge.
mRs ≤ 2 mRs > 2 p p*
Age 68 (18-93) 76.5 (23-95) 0.002 0.080
Gender
Male 42.2% 13.1%
Female 29.6% 15.0% 0.122 0.994
Hypertension 66.9% 74.1% 0.403 0.309
Diabetes 34.5% 37.9% 0.632 0.542
Smoking 16.3% 13.8% 0.831 0.357
Family history of 
stroke 8.1% 6.9% 1.000 0.291
Previous stroke or TIA 27.7% 31% 0.732 0.624
Atrial fibrillation 31.6% 40.8% 0.283 0.832
Time of symptoms 36 (30-17280) 575 (60-7200) 0.072 0.996
Wake-up stroke 22.97% 36.2% 0.079 0.796
Glucose at 
admission 113 (76-321) 115 (60-271) 0.336 0.774
SPAN-100 ≥ 100 0.67% 18.96% < 0.001 0.774
ASTRAL ≥ 31 2.7% 36.2% < 0.001 0.999
NIHSS
0 to 5 83.24% 38.46%
< 0.001 0.9996 to 15 10.86% 26.92%
≥ 16 2.9% 34.62%
THRIVE
0 to 2 62.16% 24.14%
< 0.001 0.2283 to 5 37.17% 58.62%
6 to 9 0.67% 17.24%
mRs: modified Rankin score; TIA: transient ischemic accident; SPAN-100: stroke 
prognostication using age and NIH stroke scale; NIHSS: National Institutes 
of Health stroke scale; ASTRAL: Acute Stroke Registry and Analysis of 
Lausanne; THRIVE: totaled health risks in vascular events; p: Mann-Whitney 
test; p*: Binary Logistic Regression.
Table 2. Clinical characteristics of patients according to the 
in-hospital death.
Survivors In hospital death p p*
Age 68 (24-93) 4 (0-21) 0.827 0.253
Gender
Male 50.2% 6%
1.000 0.862
Female 39.3% 4.5%
Hypertension 66.7% 81% 0.223 0.615
Diabetes 36.7% 33.3% 0.816 0.824
Smoking 16.2% 14.3% 1.000 0.516
Family history 7.8% 4.8% 1.000 0.787
Previous stroke 
or TIA 27.2% 38.1% 0.312 0.313
Atrial fibrillation 33.1% 41.2% 0.590 0.299
Time of symptoms 455 (30-17280) 430 (30-4320) 0.793 0.519
Wake-up stroke 28.9% 14.3% 0.200 0.463
Glucose at 
admission 114.5 (76-321) 111 (60-147) 0.669 0.392
SPAN-100 > 100 5.56% 9.52% 0.363 0.999
ASTRAL > 31 10.56% 23.8% 0.145 0.971
NIHSS
0 to 5 10.37% 66.66%
0.497 0.6496 to 15 15.24% 14.29%
≥ 16 74.39% 19.05%
THRIVE
0-2 55% 28.6%
0.069 0.1483-5 40% 61.9%
6-9 5% 9.5%
mRs: modified Rankin score; TIA: transient ischemic accident; SPAN-100: stroke 
prognostication using age and NIH stroke scale; NIHSS: National Institutes 
of Health stroke scale; ASTRAL: Acute Stroke Registry and Analysis of 
Lausanne; THRIVE: totaled health risks in vascular events; p: Mann-Whitney 
test; p*: Binary Logistic Regression.
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Chinese population12. ASTRAL score was previously shown 
to be a reliable predictor of 5-year functional outcome and 
mortality13 and a good predictor of unfavorable outcome 
at 3 and 12 months in Chinese population14,15. In the pres-
ent study ASTRAL poorly predicted functional outcome 
and did not predict in-hospital mortality. The difference 
between our findings and the previous studies evaluating 
ASTRAL performance must be viewed with caution. In the 
present study we evaluated in-hospital outcomes, ie, func-
tional status at discharge and in-hospital mortality, while 
the previous studies evaluated prognosis at 3 months or 
more. It is possible that these differences explain why none 
of the tested variables were independently associated with 
functional outcome and in-hospital mortality.
Our study has limitations that deserve comment. First, 
the number of included patients was small. Consequently, 
these results need confirmation in larger stroke registries or 
in prospective studies. Also, we did not follow the patients 
after discharge, so there are not data concerning 3- and 
12-month outcomes. As strengthens of the study it must 
be mentioned the homogeneity of the sample, since all the 
patients were from a single institution and the same stroke 
team evaluated all patients.
The use of prognostic scores may help clinicians, since 
the clinical evaluation alone is inaccurate16. To contribute 
to clinicians, the score must be highly effective in prognostic 
evaluation and easily applied during the first clinical evalua-
tion. The use of such scales, in this context, can help better 
target the use of therapeutic resources, especially in coun-
tries where limited resources to treat stroke patients are 
available, such as the low to medium income countries. The 
present results do not allow, to date, the recommendation of 
these scores for clinical use in Brazilian population. Future 
and larger studies are still necessary to reassess the accura-
cy of these scales, specially THRIVE which showed to be the 
most promising of the four evaluated scales.
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